Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main (gene editing) focus: In vivo base editing for genetic diseases
Company stage: Commercial
Diseases (gene editing): Rare genetic diseases of the liver, muscle and central nervous system
Genome editing tool: Base editing
Funding stage: Public (NASDAQ:PFE)
Location: New York City, New York, USA
Gene editing partnerships: Beam Therapeutics
Pfizer is an established big pharma company with worldwide operations and drug discovery activities within many different areas. The company's engagement in the gene-editing space comes through its collaboration with Beam Therapeutics. The two companies will develop novel in vivo gene-editing programmes against targets within disease areas involving the liver, muscle and central nervous system (CNS).